About Johnson & Johnson
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.jnj.com/
Frequently Asked Questions
What is the 52-week range for JNJ?
The 52-week high is $281.07 and the 52-week low is $182.94.
What is the P/E ratio for JNJ?
The Price to Earnings (P/E) ratio is 29.47.
What is the dividend yield for JNJ?
The indicated annual dividend yield is 3.12%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 25.74%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 21.48%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.13.
Analyst Recommendation Trends
Wall Street analyst consensus for JNJ over the last few months:
Latest JNJ News
Why Medtronic’s $4 Billion MiniMed Exchange Offer Is Losing Its Allure
The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
Friday's session: top gainers and losers in the dow jones index
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Dave Ramsey Says Single Stocks Are a Gamble. What That Means if You Live on Dividends
Dave Ramsey has called single stocks a gamble for years, but retirees who pay their bills with dividends from stocks like Johnson and Johnson are making a very different bet. Whether his rule protects them or costs them depends on a risk they may not see coming.
Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as
What's going on in today's session: dow jones movers
Curious about the top performers within the dow jones index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Johnson & Johnson (JNJ) IMAAVY Data Puts Its Undervalued Narrative Back In Focus
Johnson & Johnson (JNJ) is back in focus after new IMAAVY data in generalized myasthenia gravis, giving investors fresh insight into how its immunology pipeline might complement the stock’s recent double digit one year return. Despite the IMAAVY update and a string of recent drug data releases across immunology, oncology and neuroscience, Johnson & Johnson’s share price has eased in the short term, with the stock down 4.4% over the past week and 4.6% over the past month. However, a 24.8% year...
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.
8 Of 11 Sectors Rise Friday As Growth Leads
Friday's regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.
How Has Pfizer's Story Changed?
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE® (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents).
Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.
Johnson & Johnson Announces Two-year Data From Its Phase 3 ICONIC-TOTAL Study Of ICOTYDE On High-Impact Plaque Psoriasis Sites; 60% Of Patients With Scalp Psoriasis And 89% With Genital Psoriasis Achieved Site-Specific Complete Skin Clearance At Week 112
The late-breaking results, shared as an oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2026, evaluated adults and adolescents with at least moderate high-impact site
BofA thinks Wall Street is underestimating one J&J drug
Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter earnings.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
These dow jones stocks are moving in today's session
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
What Is The Options Market Telling Us About Eli Lilly Stock?
Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.
Focused Funds Can Help You Navigate a Top-Heavy Market
From January 1926 through December 2025, just 46 stocks—out of 29,754 common stocks listed on the public U.S. stock markets over that period—accounted for half of the $91 trillion in net wealth creation, according to a study published in March titled “One Hundred Years in the U.S. Stock Markets.” Worse, the median buy-and-hold return for all those stocks was minus 6.9%. Then again, if you look at Vanguard 500 from Dec. 31, 2009, until today, it gained 832% versus Yacktman’s 569%.
Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue
Jabil posted a double-beat quarter with nearly 29% revenue growth and 34% EPS growth, driven by AI demand, while maintaining buybacks and a Buy-rated analyst consensus.
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
JACKSONVILLE, Fla., October 01, 2026--New global survey by Johnson & Johnson finds most women don’t connect eye health changes with menopause
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.
Medtronic is following a strategy that has worked well for Johnson & Johnson.
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)
With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.
New Senior Commercial Appointments at Neuromod
Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer (CCO) and Shannon Basham as VP of Channel Development.
What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing?
Johnson & Johnson (NYSE:JNJ) closed at $264.74 on September 30, almost 43% higher than a year ago and within a few percent of its record. The company is worth about $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit. READ ALSO: Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid […]
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High
This is not an exhaustive list.
PepsiCo (PEP) Taps A Healthcare Chief For Its Board At A Key Moment
PepsiCo (NasdaqGS:PEP) has appointed Joaquin Duato, Chairman and CEO of Johnson & Johnson, to its Board of Directors. Duato currently leads Johnson & Johnson, a major global healthcare group with a large portfolio of consumer and pharmaceutical brands. His appointment adds senior healthcare and international experience to PepsiCo's board as the business focuses on health oriented product lines. The addition of Joaquin Duato to PepsiCo's board comes alongside broader themes our research has...
Was The Run In JNJ Stock Hiding In Plain Sight?
Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.
3 Healthcare Dividend Stocks Offering More Than Just Income
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years?
Key TakeawaysMicrosoft just raised its quarterly dividend 8% to $0. 98, and Johnson & Johnson raised its payout for the 64th straight year in April.
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
What Is Merck Stock's Biggest Opportunity?
Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does.
SHCD is missing some of the healthiest dividend stocks.
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are mostly bullish after positive Tremfya and Carvykti data.
Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data
Johnson & Johnson (NYSE:JNJ) reported new long term IMAAVY data in generalized myasthenia gravis, including adolescent outcomes. The company said adolescents with gMG on IMAAVY showed sustained disease control and reduced reliance on corticosteroids, with no new safety signals. Survey findings from healthcare professionals indicated IMAAVY may address unmet needs for more consistent symptom management in gMG treatment. The new IMAAVY findings in adolescent gMG sit alongside broader shifts...
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $267.66, marking a -1.58% move from the previous day.
Do You Really Understand ISRG Stock's Risk?
Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.
Muse AI Agent Stock Portfolio: 2 Non-AI Stock Picks You Should Not Miss
Note: The stock trades in this article come from Rallies Arena, an account on X (@ralliesarena) that runs the Rallies AI Stock Market Arena, an experiment where AI models manage stock portfolios and try to beat the S&P 500. Rallies Arena recently allocated funds to Muse AI, Meta Platform’s new AI agent that is making […]
Which dow jones stocks are moving on Tuesday?
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Defensive Dividends: 3 Companies Investors Can Rely On
Several members of the elite Dividend Kings club, including JNJ, KO, and ABBV, are known for dividend reliability, each with a long, consistent history of increasing payouts. The trio boasts a strong defensive nature given consumers' needs for their products no matter the backdrop.
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.
Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says
Johnson & Johnson (NYSE:JNJ)'s oral psoriasis drug Icotyde could reach $4.5 billion in peak sales, up from a previous $2.4 billion estimate, Bank of America said as it raised its price target on the company to $278 from $263. The broker now values estimated 2027 earnings excluding...
Uncover the latest developments among dow jones stocks in today's session.
Get insights into the dow jones index performance on Tuesday. Explore the top gainers and losers within the dow jones index in today's session.
Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?
Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight
Recently published Retinitis Pigmentosa Market Insights report includes a comprehensive understanding of current treatment practices, retinitis pigmentosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
BioFuture 2026 Convenes Industry Leaders in New York City to Explore the Trends Reshaping Biopharma and Healthcare
Demy-Colton today announced the agenda for BioFuture™ 2026, taking place October 27–28 at Cure, 345 Park Avenue South in New York City. The conference will bring together leaders from across biopharma, healthcare, investment, technology and policy for discussions, company presentations, networking and one-to-one partnering, followed by virtual partnering November 3–5.
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss
Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.
BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street
The bank raised its Icotyde forecasts but kept a Neutral rating
Johnson & Johnson's Q3 2026 Earnings: What to Expect
Johnson & Johnson will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Johnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY® (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. These data include two-year results from the Phase 2/3 study in adolescents which demonstrated sustained disease control while on IMAAVY, w
Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years
Three stocks have raised their dividends for over 30 consecutive years through recessions, wars, and market crashes, and one has paid shareholders without interruption for 136 years straight. Find out which name a 65-year-old retiree should anchor their income portfolio around.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
JP Morgan Maintains Neutral on Johnson & Johnson, Raises Price Target to $285
JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $270 to $285.
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.
Johnson & Johnson (JNJ) Stock May Be Undervalued As Its 96% Run Continues
Johnson & Johnson has delivered a strong run over the past few years, which naturally raises a question for anyone looking at the stock today. Are investors now paying a price that is fully backed by the cash flows the healthcare group is expected to generate? Over the past 5 years the share price is up 96.4%, which means a lot of future cash generation is already being referenced in the current valuation debate. Recent clinical data across therapies such as TECVAYLI, DARZALEX FASPRO,...
Johnson & Johnson To Present New Findings On IMAAVY For Treatment Of Generalized Myasthenia Gravis Across 15 Novel Abstracts At 2026 MGFA Scientific Session And AANEM Annual Meeting
New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.
Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story?
On September 25, Johnson & Johnson (NYSE:JNJ) announced top-line findings from its Phase 4 STAR study evaluating Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis (PsA) and axial involvement. Tremfya met primary and secondary endpoints, demonstrating improvements in axial symptoms alongside MRI-confirmed reductions in joint inflammation. As the first randomized, placebo-controlled study to prospectively […]
$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit
A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.
Can J&J’s Latest Trial Win Strengthen its Neuroscience Business?
Johnson & Johnson’s (NYSE:JNJ) $14.6 billion acquisition of Intra-Cellular Therapies has gained another potential growth avenue after Caplyta met the main goal of a late-stage study in bipolar mania. J&J said Caplyta significantly reduced symptoms of bipolar mania compared with placebo in the Phase 3 trial. Patients began showing improvement as early as three days […]
Can J&J’s Partnership Drive More Upside for Nanobiotix?
Guggenheim has assumed coverage of Nanobiotix S.A. (NASDAQ:NBTX) with a Buy rating and a $64 price target on September 15, putting the company’s Johnson & Johnson-partnered JNJ-1900 at the center of its investment thesis. The analyst’s attention is particularly focused on NANORAY-312, the pivotal Phase 3 study evaluating JNJ-1900 in patients with locally advanced head […]
Top dow jones movers in Monday's session
Curious about the dow jones stocks that are in motion on Monday? Join us as we explore the top movers within the dow jones index during today's session.
How Big Could BSX Stock's Next Fall Be?
Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.
How Large Does Your Portfolio Need to Be to Generate $8,350 a Month?
The portfolio size needed to generate a six-figure passive income swings by nearly $2 million depending on one decision, and getting that decision wrong could leave your monthly check vulnerable to a single dividend cut.
What Are Merck Stock Investors Overlooking?
If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarter of 2026. That was about half of Merck's $16.6 billion in quarterly revenue. Management now expects KEYTRUDA’s U.S. growth to moderate, raising questions about whether the stock's recent run has fully priced in the transition.
Johnson & Johnson’s Next Growth Engine Is Taking Shape
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull case or the headwinds win.
Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.
8 Of 11 Sectors Fall In Monday Trading As Defensives Lead
Three sectors are higher and eight are lower in Monday’s regular session, with defensive and cyclical sectors split across the top three positions. The leaders are separated rather than clustered.
Best Dividend Aristocrats For October 2026
The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]
Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns
Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.
Best Dividend Kings: September 2026
Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.
What Does Johnson & Johnson (JNJ) New Clinical Data Mean For Its Stock?
Johnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data suggest TECVAYLI plus DARZALEX FASPRO could align patient mortality risk with that of the general population. CARVYKTI results highlight treatment-free remissions lasting five years in relapsed or refractory multiple myeloma, while TREMFYA data support an axial psoriatic arthritis label...
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement
Most retirees obsess over yield and payout ratios, but neither metric has actually survived a recession, a rate spike, or a global pandemic on your behalf. One number has, and it changes everything about how you evaluate an income stock.
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study’s primary endpoint at week 24, showing greater improvement than placebo on a disease...
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Johnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor spec
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
New results from cohort A of the CARTITUDE-2 study, among 20 patients, suggest earlier treatment may increase the likelihood of long-term remission1Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control2 BEERSE, BELGIUM, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, a worldwide leader in multiple myeloma, announced today new long-te
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study (N=20) showing that 50% of patients (10/20) in early line relapsed or refractory multiple myeloma (RRMM) who were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) remained alive and progression-free for at least five years without maintenance therapy.1 These results bui
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement confirmed by
J&J’s RYBREVANT Shows Strong Survival. Is J&J’s Oncology Franchise Gaining?
Johnson & Johnson (NYSE:JNJ) already has RYBREVANT approved across multiple EGFR-mutated advanced lung cancer settings. New long-term data are now strengthening the clinical evidence behind the drug. READ ALSO: Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? In the final overall-survival analysis of the Phase 3 PAPILLON study, first-line RYBREVANT plus chemotherapy […]
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […]
Apollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue
It was reported on September 11 that Apollo Global Management, Inc. (NYSE:APO) is in discussions to acquire Johnson & Johnson (NYSE:JNJ)’s orthopedics business, DePuy Synthes, in a potential transaction valuing the unit at close to $20 billion, according to Bloomberg. The unit, which J&J previously announced plans to separate within an 18-to-24-month timeframe, generated $9.3 […]
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiationStrengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029Acceptable safety profile and promising initial efficacy responses obs
J&J Gains 1.7% as Caplyta Opens a Mania Expansion Path
Rapid symptom improvement broadens the drug's potential reach, but filing, approval and adoption remain ahead.
Stay informed with the top movers within the dow jones index on Thursday.
Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
Can This Number Push ISRG Stock Higher?
Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.
Dave Ramsey Says You Need More Than 6% Just to Break Even. Dividend Growth Is One Way to Get There.
A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb that bar year after year.
CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More
When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.
Thursday's session: top gainers and losers in the dow jones index
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104. Click to read in detail about ACIU.
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.
8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than
What J&J’s Spravato patent win could mean for psychedelic drugs
As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
Pharmaceutical Drug Delivery Market Forecasts Growth from $2.15T (2026) to $2.92T by 2031, Profiling J&J, Pfizer, Roche, BD & Novartis
The global pharmaceutical drug delivery market is projected to grow from USD 2.15 trillion in 2026 to USD 2.92 trillion by 2031, registering a 6.3% CAGR. Growth is driven by rising chronic disease prevalence, biologics, biosimilars, advanced therapies, self-administration and connected drug-device technologies. Injectable drug delivery led the market in 2025, while hospitals were the largest facility segment. North America dominated due to advanced healthcare infrastructure, strong R&D and wides
Medical Robots Market Forecasts Growth from $20.6B (2026) to $41.7B by 2031, Profiling Intuitive Surgical, Stryker, Zimmer Biomet & Medtronic
The global medical robots market is projected to grow from USD 20.6 billion in 2026 to USD 41.7 billion by 2031, at a 15.1% CAGR. Growth is driven by demand for minimally invasive surgery, healthcare automation, precision procedures, and advances in AI-powered surgical, rehabilitation, radiosurgery, hospital, and pharmacy robots. Robotic systems will hold the largest market share, while surgical robots will lead by type. Ambulatory surgery centers are set for the fastest end-user growth, and Asi
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Surgical Devices Market Size to Worth USD 27.14 Billion by 2030, at a CAGR of 14.7% – MarketsandMarkets™
Delray Beach, FL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global surgical devices market will grow from USD 188.74 billion in 2026 to USD 296.76 billion by 2031, at a CAGR of 9.5% during the forecast period. Market growth is driven by the increasing aging population, rising surgical procedures, adoption of minimally invasive and robotic surgeries, technological advancements, and expanding healthcare infrastructure globally. Get PDF Brochure - Market Data & Segmentation
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy.1,2
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
Johnson & Johnson: What the Street’s Reaction to OTTAVA Actually Reveals About the Stock
Key TakeawaysJohnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7. 89 billion to $8.
Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development
Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company focused on addressing the significant unmet medical needs of patients living with gout, today announced a series of leadership appointments that further strengthen the Company as it advances dotinurad through its registrational program.
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now
Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil
2 Stocks to Buy Hand Over Fist if a Stock Market Crash Is Coming
You can take these companies' dividends straight to the bank.
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson vs. AbbVie valuation: JNJâs P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the full analysis here.
Johnson & Johnson Announces Data From Phase 3 MajesTEC-3 Trial Demonstrates Disease Control, Survival With TECVAYLI Plus DARZALEX FASPRO To Treat Relapsed Or Refractory Multiple Myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI®
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For Shareholders
Johnson & Johnson recently reported positive topline Phase 3 results for CAPLYTA (lumateperone) in adults with bipolar I disorder experiencing manic episodes, showing rapid and statistically significant symptom reduction versus placebo, while also highlighting progress across its broader neuropsychiatry portfolio. The data suggest CAPLYTA could potentially treat both depressive and acute manic episodes in bipolar I disorder, meaningfully broadening its clinical role if future regulatory...
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
How Far Can BSX Stock Swing After Losing More Than Half Its Value?
Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.
What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?
Johnson & Johnson (NYSE: JNJ) received FDA approval for ICOTYDE (icotrokinra) to treat moderate to severe plaque psoriasis in the U.S. ICOTYDE targets the IL-23 receptor and is in Phase III clinical trials for a potential psoriatic arthritis indication. The new therapy extends Johnson & Johnson's immunology pipeline beyond oncology and MedTech into chronic inflammatory skin and joint conditions. The ICOTYDE psoriasis approval and psoriatic arthritis Phase III program deserves weighing...
Six Organizations Honored for Shaping the First Decade of Workplace Mental Health Care
In celebration of its tenth anniversary, Spring Health, a global mental health company built on one AI-native platform, named six organizations as the inaugural recipients of its Pioneer Award, honoring their leadership in advancing how employers deliver mental health benefits. At a time when workplace mental health care was still new and untested, Adobe, BASF, Cincinnati Children's, Johnson & Johnson, Koch, and Nielsen chose to invest early in a different way of caring for their people. HR and
AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization
BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
WEST CHESTER, Pa., September 22, 2026--DePuy Synthes, a global leader in orthopaedic technologies and solutions, will showcase its latest trauma innovations at the 2026 Orthopaedic Trauma Association (OTA) Annual Meeting in Nashville, including four new VOLT™ plating systems, MAXFRAME AUTOSTRUT™ with Bluetooth® Multi-Axial Correction System, VELYS™ Trauma AI Assisted Surgery enabling technology, and an expanded value offering for procedural solutions.
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win
J&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal
Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.
J&J Gains as Caplyta Opens a Mania Expansion Path
A three-week study produced rapid symptom improvement, but regulatory approval and commercial conversion remain ahead.
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth
How Far Could ISRG Stock Bounce From Here?
Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.
Does Long-Term Dividend Investing Really Work? This Study Says "Definitely."
Dividend growth stocks have outperformed other types and have done so with significantly less risk.
What Would It Take For Pfizer To Cut Its Dividend?
Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
Johnson & Johnson announces positive Phase 3 results for CAPLYTA, showing rapid reduction in bipolar I disorder manic symptoms.
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA® (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder. The study met its primary endpoint, with CAPLYTA® demonstrating a statistically significant and rapid reduction in manic symptoms versus placebo at Week 3, with significant improvement seen as early as Day 3. The findings were presented in a late-breaking prese
Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA® (lumateperone) for the treatment of manic episodes with or without mixed features in adults
How J&J paved the way for Compass’ coming psychedelic drug launch
In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.
The S&P 500 Has Returned About 11% Annually Since 1958. Here's the ETF I'd Trust for the Next 30 Years.
Investors need something that evolves with a changing economy.
PepsiCo (PEP) Adds A New Director, Is The Discount To Fair Value Warranted?
Board change puts governance in focus PepsiCo (PEP) has drawn fresh attention after appointing Johnson & Johnson chief Joaquin Duato as an independent director and Audit Committee member, steering conversation toward board oversight and long term decision making. Recent trading has been rough for PepsiCo, with the share price falling 9.0% over the past 30 days and 8.8% year to date. The 1 year total shareholder return is down 4.8% and the 3 year total shareholder return has declined 17.5%,...
What Would It Take For Eli Lilly Stock To Keep Climbing?
Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.
Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?
Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.
Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
Which dow jones stocks are moving on Friday?
Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20
Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can hold up long enough to matter.
Can Intuitive Surgical Make Up For A Lower Price Per Surgery?
Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.
Veradermics: Buy Before The Catalysts
Veradermics (MANE) stock outlook: Phase 3 VDPHL01 readouts, FDA approval odds, cash runway, and hair loss market upsideâsee the bull case and act now.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Johnson & Johnson (JNJ) Faces A Fresh Valuation Test On DePuy Sale Talk
A potential sale of DePuy Synthes for about US$20b has put Johnson & Johnson (JNJ) back in focus for investors watching how management reshapes its MedTech footprint and capital allocation priorities. The share price of Johnson & Johnson sits at US$270.22 after a 1-day share price return of 1.10% and a 90-day share price return of 18.32%. Recent oncology data and portfolio reshaping moves have contributed to a year-to-date share price return of 30.32% and a 1-year total shareholder return of...
The Dividend Kings Ranked By Quality Scores (September 2026)
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges.
A $100,000 Retirement Dividend Snowball In A Rising-Rate World
Learn how to build a $100,000 dividend snowball for passive income in todayâs rising rate marketâplus allocation tips and specific picks.
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
In the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.
PepsiCo Elects Joaquin Duato to Board of Directors
PepsiCo, Inc. (NASDAQ: PEP) today announced its Board of Directors has elected Joaquin Duato as an independent member of the Board. Mr. Duato, 64, will join the Board effective December 1, 2026, and will be a member of the Audit Committee. Mr. Duato currently serves as Chairman and Chief Executive Officer of Johnson & Johnson, a global healthcare company.
Even With $262,000 in VYM, You Wouldn’t Get a $500 Check Every Month
Retirees chasing a simple $500 monthly check from VYM run straight into a gap between how yields are calculated and how cash actually lands in your account, and the math gets uncomfortable fast.
Can Volume Keep Covering Eli Lilly's Price Cuts?
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
Is ISRG Stock Really As Expensive As It Looks?
Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff
Johnson & Johnson (NYSE:JNJ) Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility. Speaking at a Deuts
The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.
Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising
Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
What Happens To AbbVie Stock If SKYRIZI Slows Down?
AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.
Is Pfizer's New Business Big Enough To Carry The Old One?
Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.
J&J Slips as Caplyta Clears a Quality-of-Life Test
Improved sexual functioning could support adherence, expanding the strategic value of J&J's $14.6 billion acquisition.
Should You Judge JNJ Stock Without STELARA?
Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.
Why This Biotech Stock Just Got a Rare Double Upgrade
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees
Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
Recently published Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Is AbbVie the Best Dividend King to Buy in September?
It is certainly a good Dividend King to buy in September.
Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative Technology
Financing follows FDA De Novo submission and publication of positive first-in-human clinical resultsCompany strengthens leadership and Board as it advances surgical reconstruction toward commercialization and evaluates opportunities in regenerative aestheticsSAN DIEGO, CA / ACCESS Newswire / September 16, 2026 / Tempo Therapeutics, Inc. ("Tempo"), a clinical-stage regenerative medicine company pioneering synthetic biomaterials designed to promote the formation of healthy, functional tissue, toda
J&J sells Laminar LAA closure assets it bought 3 years ago
The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.
Johnson & Johnson (JNJ) Reports Stronger Survival Data In EGFR Mutated Lung Cancer
Johnson & Johnson (NYSE:JNJ) reported new clinical trial results for RYBREVANT-based regimens in EGFR-mutated NSCLC at a major oncology conference. The Phase 2b COPERNICUS study showed RYBREVANT plus LAZCLUZE for newly diagnosed patients with EGFR-mutated NSCLC had improved tolerability and fewer treatment-related adverse events. Final data from the Phase 3 PAPILLON trial found first-line RYBREVANT plus chemotherapy produced the longest reported median overall survival in EGFR exon 20...
Merck Stock: Is The $70 Billion Pipeline Worth the Premium?
A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.
Discover which dow jones stocks are making waves on Tuesday.
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Tuesday.
Has BSX Stock Finally Hit Bottom?
Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.
3 Healthcare Stocks for 3 Stages of Life
Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.
Senator Bets on Small Cap Stocks Ahead of Likely Rate Hike: Why That Could be Risky
A U.S. senator has added small cap stock ETFs to his portfolio ahead of a potential Federal Reserve rate hike. Here's why the timing matters.
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J
Apollo and J&J Face a High-Stakes Orthopedics Deal
Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction […]
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
Johnson & Johnson released positive Phase 2b and Phase 3 trial results for its Rybrevant lung cancer treatment combinations.
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
Retirees don’t need the highest yield on the board. They need the check to keep arriving, and to keep growing, through every recession, rate cycle, and regime change. Three Dividend Kings fit that brief: Coca-Cola, Johnson & Johnson, and PepsiCo. Each has raised its payout for decades without a cut, and one benchmark says it […]
Cooper Companies: A Little More Compelling At This Price
Cooper Companies (COO) upgraded to Hold after a 31% drop.
AI Safety Fears Drive Investors to J&J, Costco, and CrowdStrike for Cybersecurity
AI safety warnings sent tech stocks lower Monday, pushing investors into J&J, Eli Lilly, Kimberly-Clark, and Costco.
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxisFewer than 1% of patients discontinued treatment due to treatment-related events at one
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations. Early results show consistently low rates across key treatme
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder.
Is This LLY Stock Dip Big Enough To Be Worth Buying?
Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.
Why Is Pfizer Stock Paying You So Much To Wait?
Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.
Final Trade: JNJ, SNPS, Mag 7, KO
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition
Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline programs to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley e
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business
These alleged talks come as J&J considers what direction to take DePuy Synthes in as it spins out from the wider business.
Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing
Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpointAnalyses of the data, including prespecified exploratory endpoints, are ongoingContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now
Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Get Paid To Wait For ISRG Stock To Go On Sale
Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.
Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Johnson & Johnson (JNJ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 11:30 AM EDTCompany ParticipantsJoaquin Duato - CEO...
Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA
A Roth IRA can strip the tax burden from even the highest-yielding dividends, but only if you put the right stocks inside it. Five blue chips with records stretching back decades make a compelling case for why account placement matters as much as stock selection.
J&J in talks to sell DePuy Synthes to Apollo for $20 billion
Apollo is in discussions to acquire DePuy Synthes, which generated $9.3 billion in sales last year and could also be spun off as a public company
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
Johnson & Johnson Shares Rise on Reported Apollo Talks for Orthopedics Unit
Johnson & Johnson (NYSE:JNJ) shares rose 1. 3% to $268.
Sector Update: Healthcare Stocks Rise Premarket Monday
Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. September 14, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Nate Massari as Chief Business Officer. Nate brings more than 25 years of expe
How Much You Need Invested to Cover Your Medicare Premiums With Dividend Income
Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your specific income bracket demands.
Johnson & Johnson requires providers to share claims data to get 340B discounts
The drugmaker is the latest to impose a reporting requirement on 340B providers, saying stricter guardrails are needed to prevent duplicative discounts.
Johnson & Johnson’s RYBREVANT Combination Extends Survival To 34.3 Months In EGFR Exon 20+ Lung Cancer
https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer
Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
Amivantamab plus chemotherapy demonstrates durable benefit with a differentiated approach that dual targets EGFR and MET1Median overall survival reached 34.3 months with the amivantamab-based regimen, the longest reported to date in this patient population1,2 BEERSE, BELGIUM, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT®▼ (amivantamab) plus
Zacks Investment Ideas feature highlights: Johnson & Johnson, Coca-Cola and Exxon Mobil
Johnson & Johnson, Coca-Cola and Exxon Mobil have been highlighted in this Investment Ideas article.
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. Patients treated with the combination achieved a median OS of nearly three years (34.3 mon
Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survival Analysis
RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and METResults mark significant progress for a patient population with poor outcomes and a historical
C3.ai (AI) Just Posted Its Most Promising Quarter In Years
On September 2, C3.ai (NYSE:AI) reported its first quarter of fiscal 2027, and the numbers finally matched the promises. Total revenue reached $52.4 million, subscription revenue made up 94% of that at $49.2 million, and total bookings jumped 73% quarter over quarter. Chief Executive Officer Tom Siebel, three months back in the role, said the […]
The Closest Thing to Set-It-and-Forget-It Income: 5 Dividend Kings for Retirees Who Want Peace of Mind
Some companies have raised their dividends through recessions, pandemics, wars, and market crashes without missing a single year, and five of them may be the steadiest income plays a retiree can own right now.
How Much Do You Really Need Invested in Dividend Stocks to Replace a $25,000 Income?
The math behind living off dividends exposes a brutal tradeoff: every percentage point of extra yield you chase to shrink your required capital brings a hidden cost that most income investors never price in before sizing their positions.
Johnson & Johnson (NYSE:JNJ): A Dividend Quality Pick for Income Investors
JNJ fits ChartMill's Best Dividend Stocks screen for income investors: 3.12% yield, durable dividend growth, strong profitability, and solid health.
2 Outstanding Dividend Stocks to Buy and Hold for 10 Years
Income seekers can't go wrong with these companies.
JNJ Stock Edges Up After-Hours On Apollo’s $20B Orthopedics Talks
People familiar with the discussions told Bloomberg that Apollo is working toward a valuation of close to $20 billion for the unit, known as DePuy Synthes.
Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit
Alternative asset manager Apollo Global Management Inc. is in discussions to acquire the Johnson & Johnson orthopedics unit that the conglomerate has been looking to separate, according to people familiar with the matter.
Jaguar LAA, Inc. Announces Acquisition of Assets Related to the Laminar Program
Jaguar LAA, Inc. ("Jaguar"), a privately held medical device company, today announced the acquisition of assets related to the Laminar program, focused on addressing the left atrial appendage ("LAA") in patients with non-valvular atrial fibrillation ("AFib"), from Johnson & Johnson.
Is AbbVie Stock Actually Overpriced?
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
Richest NFL Team Owners List: Who’s Most Connected to Stock Market?
The list of NFL team owners includes billionaires and families. Some of them are well connected to publicly traded companies.
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
3 Top Dividend Aristocrats To Own Near All-Time Highs
Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting bullish momentum driven by strong results or favorable operating conditions.
These 5 Dividend Stocks Survived 2008, COVID and Every Recession Before Them
Chasing the fattest yield on the screen is a trap most income investors fall into, but a handful of companies have quietly raised their payouts through oil shocks, financial meltdowns, and a global pandemic without skipping a beat. The question is what they all have in common.
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
IHE trades at a P/E of 16.11x and is rated HOLD due to regulatory, patent, and concentration risks. Click for more details on the IHE fund.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.
Which dow jones stocks are moving on Thursday?
Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Woods Eugene A. | +136 | $276.31 | $37,578 |
| 2026-09-08 | Pinto Daniel E | +113 | $276.31 | $31,223 |
| 2026-09-08 | HEWSON MARILLYN A | +181 | $276.31 | $50,012 |
| 2026-09-02 | Schmid Timothy | -22,527 | - | - |
| 2026-09-02 | Schmid Timothy | -11,070 | - | - |
| 2026-09-02 | Schmid Timothy | -22,527 | $274.74 | $6,189,068 |
| 2026-09-02 | Schmid Timothy | +22,527 | $151.41 | $3,410,813 |
| 2026-09-02 | Schmid Timothy | -11,070 | $274.74 | $3,041,372 |
| 2026-09-02 | Schmid Timothy | +11,070 | $131.94 | $1,460,576 |
| 2026-08-17 | Taubert Jennifer L | -15,000 | - | - |
| 2026-08-17 | Taubert Jennifer L | -15,000 | $263.36 | $3,950,400 |
| 2026-08-17 | Taubert Jennifer L | +15,000 | $115.67 | $1,735,050 |
| 2026-08-13 | Duato Joaquin | -123,291 | - | - |
| 2026-08-13 | Duato Joaquin | -102,315 | $261 | $26,704,215 |
| 2026-08-13 | Duato Joaquin | -20,976 | $262 | $5,495,712 |
| 2026-08-13 | Duato Joaquin | +123,291 | $115.67 | $14,261,070 |
| 2026-08-06 | Forminard Elizabeth | -9,344 | - | - |
| 2026-08-06 | Forminard Elizabeth | -6,574 | $255.932 | $1,682,497 |
| 2026-08-06 | Forminard Elizabeth | -9,344 | $257.755 | $2,408,463 |
| 2026-08-06 | Forminard Elizabeth | +9,344 | $131.94 | $1,232,847 |
| 2026-08-05 | Duato Joaquin | -6,523 | $258.739 | $1,687,754 |
| 2026-08-05 | Duato Joaquin | -41,957 | $258.056 | $10,827,256 |
| 2026-07-20 | Broadhurst Vanessa | -11,925 | - | - |
| 2026-07-20 | Broadhurst Vanessa | -11,129 | - | - |
| 2026-07-20 | Broadhurst Vanessa | -23,054 | $251.266 | $5,792,686 |
| 2026-07-20 | Broadhurst Vanessa | +11,925 | $131.94 | $1,573,385 |
| 2026-07-20 | Broadhurst Vanessa | +11,129 | $129.51 | $1,441,317 |
| 2026-06-11 | Wengel Kathryn E | -10,000 | - | - |
| 2026-06-11 | Wengel Kathryn E | -10,000 | $241.15 | $2,411,500 |
| 2026-06-11 | Wengel Kathryn E | +10,000 | $115.67 | $1,156,700 |
| 2026-06-09 | Woods Eugene A. | +161 | $232.79 | $37,479 |
| 2026-06-09 | Pinto Daniel E | +134 | $232.79 | $31,194 |
| 2026-06-09 | HEWSON MARILLYN A | +215 | $232.79 | $50,050 |
| 2026-05-01 | REED JOHN C | -25,255 | - | - |
| 2026-05-01 | REED JOHN C | -11,002 | $229.85 | $2,528,810 |
| 2026-05-01 | REED JOHN C | +25,255 | - | - |
| 2026-04-23 | West Nadja | +975 | - | - |
| 2026-04-23 | WEINBERGER MARK A | +975 | - | - |
| 2026-04-23 | Woods Eugene A. | +975 | - | - |
| 2026-04-23 | Doudna Jennifer A | +975 | - | - |
| 2026-04-23 | McClellan Mark B. | +975 | - | - |
| 2026-04-23 | Pinto Daniel E | +1,712 | - | - |
| 2026-04-23 | Beckerle Mary C | +975 | - | - |
| 2026-04-23 | Joly Hubert | +975 | - | - |
| 2026-04-23 | Johnson Paula A | +975 | - | - |
| 2026-04-23 | HEWSON MARILLYN A | +975 | - | - |
| 2026-04-23 | MORIKIS JOHN G | +1,540 | - | - |
| 2026-03-10 | Woods Eugene A. | +155 | $242.14 | $37,532 |
| 2026-03-10 | Pinto Daniel E | +129 | $242.14 | $31,236 |
| 2026-03-10 | HEWSON MARILLYN A | +206 | $242.14 | $49,881 |
| 2026-02-27 | Decker Robert J | -4,075 | - | - |
| 2026-02-27 | Decker Robert J | -4,075 | $247.87 | $1,010,070 |
| 2026-02-27 | Decker Robert J | +4,075 | $115.67 | $471,355 |
| 2026-02-20 | Schmid Timothy | -1,322 | $245.66 | $324,763 |
| 2026-02-18 | Schmid Timothy | -8,998 | - | - |
| 2026-02-18 | Schmid Timothy | -13,625 | - | - |
| 2026-02-18 | Schmid Timothy | -8,998 | $244.53 | $2,200,281 |
| 2026-02-18 | Schmid Timothy | +8,998 | $129.51 | $1,165,331 |
| 2026-02-18 | Schmid Timothy | -13,625 | $244.2 | $3,327,225 |
| 2026-02-18 | Schmid Timothy | +13,625 | $115.67 | $1,576,004 |
| 2026-02-17 | Broadhurst Vanessa | -6,197 | $243.39 | $1,508,288 |
| 2026-02-17 | Swanson James D. | -20,521 | - | - |
| 2026-02-17 | Swanson James D. | -20,521 | $242.7 | $4,980,447 |
| 2026-02-17 | Swanson James D. | +20,521 | $164.62 | $3,378,167 |
| 2026-02-17 | Wolk Joseph J | -33,386 | - | - |
| 2026-02-17 | Wolk Joseph J | -12,066 | - | - |
| 2026-02-17 | Wolk Joseph J | -19,241 | - | - |
| 2026-02-17 | Wolk Joseph J | -24,961 | $242.68 | $6,057,535 |
| 2026-02-17 | Wolk Joseph J | -33,386 | $242.75 | $8,104,452 |
| 2026-02-17 | Wolk Joseph J | +33,386 | $131.94 | $4,404,949 |
| 2026-02-17 | Wolk Joseph J | -12,066 | $242.87 | $2,930,469 |
| 2026-02-17 | Wolk Joseph J | +12,066 | $129.51 | $1,562,668 |
| 2026-02-17 | Wolk Joseph J | -19,241 | $242.99 | $4,675,371 |
| 2026-02-17 | Wolk Joseph J | +19,241 | $115.67 | $2,225,606 |
| 2026-02-17 | REED JOHN C | -29,927 | - | - |
| 2026-02-17 | REED JOHN C | -21,721 | - | - |
| 2026-02-17 | REED JOHN C | -2,283 | $243 | $554,769 |
| 2026-02-17 | REED JOHN C | -29,927 | $243 | $7,272,261 |
| 2026-02-17 | REED JOHN C | +29,927 | $156.15 | $4,673,101 |
| 2026-02-17 | REED JOHN C | -21,721 | $243 | $5,278,203 |
| 2026-02-17 | REED JOHN C | +21,721 | $157.92 | $3,430,180 |
| 2026-02-15 | Mulholland Kristen | +1,459 | - | - |
| 2026-02-15 | Mulholland Kristen | +20,322 | - | - |
| 2026-02-15 | Mulholland Kristen | -575 | - | - |
| 2026-02-15 | Mulholland Kristen | -419 | - | - |
| 2026-02-15 | Mulholland Kristen | -251 | $243.45 | $61,106 |
| 2026-02-15 | Mulholland Kristen | +575 | - | - |
| 2026-02-15 | Mulholland Kristen | -172 | $243.45 | $41,873 |
| 2026-02-15 | Mulholland Kristen | +419 | - | - |
| 2026-02-15 | Schmid Timothy | +2,548 | - | - |
| 2026-02-15 | Schmid Timothy | +35,489 | - | - |
| 2026-02-15 | Schmid Timothy | -1,026 | - | - |
| 2026-02-15 | Schmid Timothy | -1,028 | - | - |
| 2026-02-15 | Schmid Timothy | -448 | $243.45 | $109,066 |
| 2026-02-15 | Schmid Timothy | +1,026 | - | - |
| 2026-02-15 | Schmid Timothy | -15 | $243.45 | $3,652 |
| 2026-02-15 | Schmid Timothy | +1,028 | - | - |
| 2026-02-15 | Forminard Elizabeth | +1,944 | - | - |
| 2026-02-15 | Forminard Elizabeth | +27,076 | - | - |
| 2026-02-15 | Forminard Elizabeth | -1,063 | - | - |
| 2026-02-15 | Forminard Elizabeth | -961 | - | - |
| 2026-02-15 | Forminard Elizabeth | -544 | $243.45 | $132,437 |
| 2026-02-15 | Forminard Elizabeth | +1,063 | - | - |
| 2026-02-15 | Forminard Elizabeth | -492 | $243.45 | $119,777 |
| 2026-02-15 | Forminard Elizabeth | +961 | - | - |
| 2026-02-15 | Broadhurst Vanessa | +1,034 | - | - |
| 2026-02-15 | Broadhurst Vanessa | +14,405 | - | - |
| 2026-02-15 | Broadhurst Vanessa | -526 | - | - |
| 2026-02-15 | Broadhurst Vanessa | -492 | - | - |
| 2026-02-15 | Broadhurst Vanessa | -270 | $243.45 | $65,732 |
| 2026-02-15 | Broadhurst Vanessa | +526 | - | - |
| 2026-02-15 | Broadhurst Vanessa | -252 | $243.45 | $61,349 |
| 2026-02-15 | Broadhurst Vanessa | +492 | - | - |
| 2026-02-15 | Swanson James D. | +1,397 | - | - |
| 2026-02-15 | Swanson James D. | +19,449 | - | - |
| 2026-02-15 | Swanson James D. | -709 | - | - |
| 2026-02-15 | Swanson James D. | -492 | - | - |
| 2026-02-15 | Swanson James D. | -309 | $243.45 | $75,226 |
| 2026-02-15 | Swanson James D. | +709 | - | - |
| 2026-02-15 | Swanson James D. | -214 | $243.45 | $52,098 |
| 2026-02-15 | Swanson James D. | +492 | - | - |
| 2026-02-15 | Decker Robert J | +700 | - | - |
| 2026-02-15 | Decker Robert J | +4,871 | - | - |
| 2026-02-15 | Decker Robert J | -344 | - | - |
| 2026-02-15 | Decker Robert J | -339 | - | - |
| 2026-02-15 | Decker Robert J | -95 | $243.45 | $23,128 |
| 2026-02-15 | Decker Robert J | +344 | - | - |
| 2026-02-15 | Decker Robert J | -94 | $243.45 | $22,884 |
| 2026-02-15 | Decker Robert J | +339 | - | - |
| 2026-02-15 | Wengel Kathryn E | +1,217 | - | - |
| 2026-02-15 | Wengel Kathryn E | +16,945 | - | - |
| 2026-02-15 | Wengel Kathryn E | -635 | - | - |
| 2026-02-15 | Wengel Kathryn E | -606 | - | - |
| 2026-02-15 | Wengel Kathryn E | -325 | $243.45 | $79,121 |
| 2026-02-15 | Wengel Kathryn E | +635 | - | - |
| 2026-02-15 | Wengel Kathryn E | -310 | $243.45 | $75,470 |
| 2026-02-15 | Wengel Kathryn E | +606 | - | - |
| 2026-02-15 | Taubert Jennifer L | +3,940 | - | - |
| 2026-02-15 | Taubert Jennifer L | +54,869 | - | - |
| 2026-02-15 | Taubert Jennifer L | -1,847 | - | - |
| 2026-02-15 | Taubert Jennifer L | -1,594 | - | - |
| 2026-02-15 | Taubert Jennifer L | -945 | $243.45 | $230,060 |
| 2026-02-15 | Taubert Jennifer L | +1,847 | - | - |
| 2026-02-15 | Taubert Jennifer L | -816 | $243.45 | $198,655 |
| 2026-02-15 | Taubert Jennifer L | +1,594 | - | - |
| 2026-02-15 | Wolk Joseph J | +3,863 | - | - |
| 2026-02-15 | Wolk Joseph J | +53,793 | - | - |
| 2026-02-15 | Wolk Joseph J | -1,878 | - | - |
| 2026-02-15 | Wolk Joseph J | -1,971 | - | - |
| 2026-02-15 | Wolk Joseph J | -817 | $243.45 | $198,899 |
| 2026-02-15 | Wolk Joseph J | +1,878 | - | - |
| 2026-02-15 | Wolk Joseph J | -858 | $243.45 | $208,880 |
| 2026-02-15 | Wolk Joseph J | +1,971 | - | - |
| 2026-02-15 | Duato Joaquin | +9,459 | - | - |
| 2026-02-15 | Duato Joaquin | +131,734 | - | - |
| 2026-02-15 | Duato Joaquin | -4,505 | - | - |
| 2026-02-15 | Duato Joaquin | -3,682 | - | - |
| 2026-02-15 | Duato Joaquin | -1,960 | $243.45 | $477,162 |
| 2026-02-15 | Duato Joaquin | +4,505 | - | - |
| 2026-02-15 | Duato Joaquin | -1,602 | $243.45 | $390,007 |
| 2026-02-15 | Duato Joaquin | +3,682 | - | - |
| 2026-02-15 | REED JOHN C | +3,546 | - | - |
| 2026-02-15 | REED JOHN C | +49,382 | - | - |
| 2026-02-15 | REED JOHN C | -1,847 | - | - |
| 2026-02-15 | REED JOHN C | -1,349 | - | - |
| 2026-02-15 | REED JOHN C | -528 | $243.45 | $128,542 |
| 2026-02-15 | REED JOHN C | +1,847 | - | - |
| 2026-02-15 | REED JOHN C | -385 | $243.45 | $93,728 |
| 2026-02-15 | REED JOHN C | +1,349 | - | - |
| 2026-02-13 | Mulholland Kristen | -3,602 | - | - |
| 2026-02-13 | Mulholland Kristen | -410 | - | - |
| 2026-02-13 | Mulholland Kristen | -1,027 | $244.55 | $251,153 |
| 2026-02-13 | Mulholland Kristen | +3,602 | - | - |
| 2026-02-13 | Mulholland Kristen | -135 | $244.55 | $33,014 |
| 2026-02-13 | Mulholland Kristen | +410 | - | - |
| 2026-02-13 | Schmid Timothy | -4,378 | - | - |
| 2026-02-13 | Schmid Timothy | -499 | - | - |
| 2026-02-13 | Schmid Timothy | -1,816 | $244.55 | $444,103 |
| 2026-02-13 | Schmid Timothy | +4,378 | - | - |
| 2026-02-13 | Schmid Timothy | -8 | $244.55 | $1,956 |
| 2026-02-13 | Schmid Timothy | +499 | - | - |
| 2026-02-13 | Forminard Elizabeth | -13,706 | - | - |
| 2026-02-13 | Forminard Elizabeth | -651 | - | - |
| 2026-02-13 | Forminard Elizabeth | -7,011 | $244.55 | $1,714,540 |
| 2026-02-13 | Forminard Elizabeth | +13,706 | - | - |
| 2026-02-13 | Forminard Elizabeth | -314 | $244.55 | $76,789 |
| 2026-02-13 | Forminard Elizabeth | +651 | - | - |
| 2026-02-13 | Broadhurst Vanessa | -8,594 | - | - |
| 2026-02-13 | Broadhurst Vanessa | -408 | - | - |
| 2026-02-13 | Broadhurst Vanessa | -3,748 | $244.55 | $916,573 |
| 2026-02-13 | Broadhurst Vanessa | +8,594 | - | - |
| 2026-02-13 | Broadhurst Vanessa | -144 | $244.55 | $35,215 |
| 2026-02-13 | Broadhurst Vanessa | +408 | - | - |
| 2026-02-13 | Swanson James D. | -22,191 | - | - |
| 2026-02-13 | Swanson James D. | -19,368 | - | - |
| 2026-02-13 | Swanson James D. | -9,412 | - | - |
| 2026-02-13 | Swanson James D. | -447 | - | - |
| 2026-02-13 | Swanson James D. | -22,191 | $243.71 | $5,408,169 |
| 2026-02-13 | Swanson James D. | +22,191 | $162.75 | $3,611,585 |
| 2026-02-13 | Swanson James D. | -19,368 | $243.76 | $4,721,144 |
| 2026-02-13 | Swanson James D. | +19,368 | $165.89 | $3,212,958 |
| 2026-02-13 | Swanson James D. | -3,547 | $244.55 | $867,419 |
| 2026-02-13 | Swanson James D. | +9,412 | - | - |
| 2026-02-13 | Swanson James D. | -143 | $244.55 | $34,971 |
| 2026-02-13 | Swanson James D. | +447 | - | - |
| 2026-02-13 | Decker Robert J | -2,741 | - | - |
| 2026-02-13 | Decker Robert J | -312 | - | - |
| 2026-02-13 | Decker Robert J | -762 | $244.55 | $186,347 |
| 2026-02-13 | Decker Robert J | +2,741 | - | - |
| 2026-02-13 | Decker Robert J | -104 | $244.55 | $25,433 |
| 2026-02-13 | Decker Robert J | +312 | - | - |
| 2026-02-13 | Wengel Kathryn E | -13,706 | - | - |
| 2026-02-13 | Wengel Kathryn E | -651 | - | - |
| 2026-02-13 | Wengel Kathryn E | -6,414 | $244.55 | $1,568,544 |
| 2026-02-13 | Wengel Kathryn E | +13,706 | - | - |
| 2026-02-13 | Wengel Kathryn E | -217 | $244.55 | $53,067 |
| 2026-02-13 | Wengel Kathryn E | +651 | - | - |
| 2026-02-13 | Taubert Jennifer L | -27,412 | - | - |
| 2026-02-13 | Taubert Jennifer L | -1,302 | - | - |
| 2026-02-13 | Taubert Jennifer L | -13,547 | $244.55 | $3,312,919 |
| 2026-02-13 | Taubert Jennifer L | +27,412 | - | - |
| 2026-02-13 | Taubert Jennifer L | -409 | $244.55 | $100,021 |
| 2026-02-13 | Taubert Jennifer L | +1,302 | - | - |
| 2026-02-13 | Wolk Joseph J | -1,779 | - | - |
| 2026-02-13 | Wolk Joseph J | -37,463 | - | - |
| 2026-02-13 | Wolk Joseph J | -507 | $244.55 | $123,987 |
| 2026-02-13 | Wolk Joseph J | +1,779 | - | - |
| 2026-02-13 | Wolk Joseph J | -15,948 | $244.55 | $3,900,083 |
| 2026-02-13 | Wolk Joseph J | +37,463 | - | - |
| 2026-02-13 | Duato Joaquin | -73,054 | - | - |
| 2026-02-13 | Duato Joaquin | -3,469 | - | - |
| 2026-02-13 | Duato Joaquin | -31,679 | $244.55 | $7,747,099 |
| 2026-02-13 | Duato Joaquin | +73,054 | - | - |
| 2026-02-13 | Duato Joaquin | -989 | $244.55 | $241,860 |
| 2026-02-13 | Duato Joaquin | +3,469 | - | - |
| 2026-02-09 | Mulholland Kristen | +3,602 | - | - |
| 2026-02-09 | Schmid Timothy | +4,378 | - | - |
| 2026-02-09 | Forminard Elizabeth | +13,706 | - | - |
| 2026-02-09 | Broadhurst Vanessa | +8,594 | - | - |
| 2026-02-09 | Swanson James D. | +9,412 | - | - |
| 2026-02-09 | Decker Robert J | +2,741 | - | - |
| 2026-02-09 | Wengel Kathryn E | +13,706 | - | - |
| 2026-02-09 | Taubert Jennifer L | +27,412 | - | - |
| 2026-02-09 | Wolk Joseph J | +37,463 | - | - |
| 2026-02-09 | Duato Joaquin | +73,054 | - | - |
| 2026-02-06 | Schmid Timothy | -15,571 | $101.87 | $1,586,218 |
| 2026-02-06 | Schmid Timothy | -10,335 | $239.99 | $2,480,297 |
| 2026-02-06 | Schmid Timothy | +15,571 | $101.87 | $1,586,218 |
| 2026-02-06 | Mulholland Kristen | -5,625 | $101.87 | $573,019 |
| 2026-02-06 | Mulholland Kristen | -3,335 | $239.99 | $800,367 |
| 2026-02-06 | Mulholland Kristen | +5,625 | $101.87 | $573,019 |
| 2026-02-06 | Wengel Kathryn E | -38,945 | $101.87 | $3,967,327 |
| 2026-02-06 | Wengel Kathryn E | -27,270 | $239.99 | $6,544,527 |
| 2026-02-06 | Wengel Kathryn E | +38,945 | $101.87 | $3,967,327 |
| 2026-02-05 | Forminard Elizabeth | -8,921 | $129.51 | $1,155,359 |
| 2026-02-05 | Forminard Elizabeth | -6,226 | $237.9 | $1,481,165 |
| 2026-02-05 | Forminard Elizabeth | +8,921 | $129.51 | $1,155,359 |
| 2026-01-26 | Duato Joaquin | -48,782 | $221.484 | $10,804,432 |
| 2026-01-26 | Duato Joaquin | -51,218 | $220.986 | $11,318,461 |
| 2025-12-09 | Woods Eugene A. | +186 | $202.12 | $37,594 |
| 2025-12-09 | Pinto Daniel E | +155 | $202.12 | $31,329 |
| 2025-12-09 | HEWSON MARILLYN A | +247 | $202.12 | $49,924 |
| 2025-11-26 | MORIKIS JOHN G | +1,250 | $206.15 | $257,688 |
| 2025-10-17 | REED JOHN C | -21,721 | $157.92 | $3,430,180 |
| 2025-10-17 | REED JOHN C | -21,721 | $192.7072 | $4,185,793 |
| 2025-10-17 | REED JOHN C | +21,721 | $157.92 | $3,430,180 |